Telehealth model versus in-person standard care for persons with type 1 diabetes treated with multiple daily injections: an open-label randomized controlled trial.
chronic complications
emerging technologies
metabolic control
telehealth
type 1 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
02
2023
accepted:
06
06
2023
medline:
17
7
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
Increasing evidence indicates that the telehealth (TH) model is noninferior to the in-person approach regarding metabolic control in type 1 diabetes (T1D) and offers advantages such as a decrease in travel time and increased accessibility for shorter/frequent visits. The primary aim of this study was to compare the change in glycated hemoglobin (HbA Randomized controlled, open-label, parallel-arm study among adults with T1D. Participants were submitted to in-person visits at baseline and at months 3 and 6 (conventional group) or teleconsultation in months 1 to 4 plus 2 in-person visits (baseline and 6 months) (TH group). Mixed effects models estimated differences in HbA Fifty-five participants were included (29 conventional/26 TH). No significant differences in HbA The TH model is comparable to in-person visits regarding HbA
Identifiants
pubmed: 37441496
doi: 10.3389/fendo.2023.1176765
pmc: PMC10333924
doi:
Substances chimiques
Glycated Hemoglobin
0
Blood Glucose
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1176765Informations de copyright
Copyright © 2023 Ballesta, Chillarón, Inglada, Climent, Llauradó, Pedro-Botet, Cots, Camell, Flores and Benaiges.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167
pubmed: 33298422
J Diabetes Sci Technol. 2014 Jul;8(4):859-64
pubmed: 24876414
Diabetes Technol Ther. 2021 Sep;23(9):642-651
pubmed: 33851873
Acta Diabetol. 2018 Feb;55(2):185-192
pubmed: 29209814
Endocrinol Metab Clin North Am. 2020 Dec;49(4):667-678
pubmed: 33153673
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84
pubmed: 33298417
Diabet Med. 2022 May;39(5):e14791
pubmed: 35028992
Diabetes Care. 2021 Jan;44(Suppl 1):S125-S150
pubmed: 33298421
Diabetes Technol Ther. 2014 Jul;16(7):435-41
pubmed: 24528195
Prim Care Diabetes. 2022 Dec;16(6):745-752
pubmed: 36266163
Diabetes Technol Ther. 2016 Jun;18(6):385-90
pubmed: 27196443
Lancet Diabetes Endocrinol. 2018 Feb;6(2):143-156
pubmed: 28867311
Curr Opin Endocrinol Diabetes Obes. 2022 Aug 1;29(4):397-402
pubmed: 35777972
Diabetes Care. 2021 Jun;44(6):1447-1450
pubmed: 33849938
J Endocrinol Invest. 2022 Sep;45(9):1663-1671
pubmed: 35476320
Front Pharmacol. 2017 May 30;8:330
pubmed: 28611672
Diabetes Care. 2020 Feb;43(2):337-342
pubmed: 31831473
Aten Primaria. 2002 May 15;29(8):517-21
pubmed: 12031227
Prev Chronic Dis. 2018 Jan 25;15:E13
pubmed: 29369757
Lancet Diabetes Endocrinol. 2022 Jan;10(1):8-10
pubmed: 34838158